Study: omega-3s benefit wide range of patients

8 July 2007

New research suggests that people with heart disease and type 2 diabetes, mothers and children, and those considered at risk of related disorders may benefit from consuming omega-3 polyunsaturated fatty acids derived from fish oils. The findings are published in the June 2007 editions of the Fats of Life e-newsletter and the PUFA (polyunsaturated fatty acid) newsletter for health professionals.

The study, which was conducted by researchers in Japan, examined the effects of the addition of eicosapentenoic acid to cholesterol-lowering statins in more than 18,000 patients with high cholesterol and triglyceride levels over a four and a half year period.

The results showed that EPA plus a statin brought about a 19% reduction in the number of coronary events compared with those using statins alone. In addition, the combination was associated with 19% fewer non-fatal coronary episodes and a 24% reduction in heart spasms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight